Left ventricular hypertrophy is more prominent in patients with primary aldosteronism than in patients with other types of secondary hypertension.

We determined functional and morphological changes of the heart by 2-dimensional and pulse Doppler echocardiography in 20 patients with primary aldosteronism and compared the results with those in 50 healthy normotensive subjects, 12 patients with Cushing's syndrome, 9 patients with pheochromocytoma, and 47 patients with essential hypertension. All hypertensive groups had greater left ventricular mass indexes than did the normotensive group (76.9 +/- 17.2 g/m2). Despite similar age distribution, blood pressure during antihypertensive treatment, and duration of hypertension, the primary aldosteronism group had a significantly greater left ventricular mass index (152.5 +/- 42.5 g/m2) than did the Cushing's syndrome (103.4 +/- 37.5 g/m2), pheochromocytoma (122.4 +/- 28.5 g/m2), and essential hypertension (101.4 +/- 32.8 g/m2) groups. The left ventricular posterior wall thickness and interventricular septal wall thickness were significantly greater in the hypertensive groups than in the normotensive group and also significantly greater in the primary aldosteronism group than in any of the other hypertensive groups. By contrast, there were no significant differences among the four hypertensive groups in any variable of systolic or diastolic function of the heart. The results suggest that left ventricular hypertrophy is more pronounced in patients with primary aldosteronism than in patients with other forms of hypertension. It is therefore important to echocardiographically evaluate cardiac hypertrophy as a risk factor of morbidity and mortality in patients with this low renin hypertension.

[1]  K. Weber,et al.  Structural remodeling in hypertensive heart disease and the role of hormones. , 1994, Hypertension.

[2]  H. Matsuoka,et al.  Myocardial Scintigraphic Characteristics in Patients With Primary Aldosteronism , 1994, Hypertension.

[3]  K. Weber,et al.  Angiotensin II and aldosterone receptor binding in rat heart and kidney: response to chronic angiotensin II or aldosterone administration. , 1993, The Journal of laboratory and clinical medicine.

[4]  K. Weber,et al.  Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. , 1993, Journal of molecular and cellular cardiology.

[5]  K. Weber,et al.  Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. , 1993, The American journal of cardiology.

[6]  J. Kaufman,et al.  Influence of arterial blood pressure and aldosterone on left ventricular hypertrophy in moderate essential hypertension. , 1993, The American journal of cardiology.

[7]  B. Swynghedauw,et al.  Role of mechanical and hormonal factors in cardiac remodeling and the biologic limits of myocardial adaptation. , 1993, The American journal of cardiology.

[8]  R. Devereux,et al.  Mechanism, effects, and reversal of left ventricular hypertrophy in hypertension. , 1993, Current opinion in nephrology and hypertension.

[9]  J. Laragh,et al.  Left ventricular mass as a measure of preclinical hypertensive disease. , 1992, American journal of hypertension.

[10]  T. Janota,et al.  Heart in adrenal diseases. , 1992, Cor et vasa.

[11]  J. Laragh,et al.  Clinical evaluation and differential diagnosis of the individual hypertensive patient. , 1991, Clinical chemistry.

[12]  K. Weber,et al.  Pathological Hypertrophy and Cardiac Interstitium: Fibrosis and Renin‐Angiotensin‐Aldosterone System , 1991, Circulation.

[13]  J. S. Janicki,et al.  Coronary vascular remodeling and myocardial fibrosis in the rat with renovascular hypertension. Response to captopril. , 1991, American journal of hypertension.

[14]  J. Laragh,et al.  Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. , 1991, Annals of internal medicine.

[15]  J. Laragh,et al.  Echocardiographic left ventricular mass and electrolyte intake predict arterial hypertension. , 1991, Annals of internal medicine.

[16]  J. S. Janicki,et al.  Remodeling of the rat right and left ventricles in experimental hypertension. , 1990, Circulation research.

[17]  D. Levy,et al.  Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. , 1990, The New England journal of medicine.

[18]  B. Massie,et al.  Hypertensive Heart Disease: The Critical Role of Left Ventricular Hypertrophy , 1989, Journal of cardiovascular pharmacology.

[19]  J. C. Christiansen,et al.  Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study. , 2020, Annals of internal medicine.

[20]  P. Macfarlane,et al.  Regression of electrocardiographic left ventricular hypertrophy following treatment of primary hyperaldosteronism. , 1988, Journal of human hypertension.

[21]  A. Labovitz,et al.  Evaluation of left ventricular diastolic function: clinical relevance and recent Doppler echocardiographic insights. , 1987, American heart journal.

[22]  G Olivetti,et al.  Quantitative structural analysis of the myocardium during physiologic growth and induced cardiac hypertrophy: a review. , 1986, Journal of the American College of Cardiology.

[23]  N Reichek,et al.  Echocardiographic Determination of Left Ventricular Mass in Man: Anatomic Validation of the Method , 1977, Circulation.

[24]  J. Brown,et al.  Renal abnormalities and vascular complications in primary hyperaldosteronism. Evidence on tertiary hyperaldosteronism. , 1976, The Quarterly journal of medicine.

[25]  J. Laragh,et al.  Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease. , 1972, The American journal of medicine.

[26]  J. Conn.  PLASMA RENIN ACTIVITY IN PRIMARY ALDOSTERONISM. IMPORTANCE IN DIFFERENTIAL DIAGNOSIS AND IN RESEARCH OF ESSENTIAL HYPERTENSION. , 1964, JAMA.

[27]  J. Laragh,et al.  Aldosterone secretion and primary and malignant hypertension. , 1960, The Journal of clinical investigation.